Synapse Biomedical said it landed $2.4 million in funding from the Ohio Third Frontier Commission for the next generation of its NeuRx technology.
The NeuRx device is designed to provide electrical stimulation to the muscles and nerves of the diaphragm. It won FDA approval in 2008, and again in 2011, specifically for treating chronic hypoventilation from amyotrophic lateral sclerosis.
The Oberlin, Ohio-based medical device company plans on expanding the NeuRx for use in managing critical care patients with respiratory insufficiency.
“This is an important award for Synapse Biomedical which will significantly accelerate timing of our next clinical trial. We anticipate the NeuRx and Transloc technology will lead to a reduction in length of stay (LOS) and improved outcomes for critical care patients. This support from the Ohio Third Frontier Commission is an important third component in our public, academic and private partnership to make these devices available,” president and CEO Anthony Ignagni said in prepared remarks.